Shopping Cart 0
Cart Subtotal
USD 0

Xbrane Biopharma AB (XBRANE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

Xbrane Biopharma AB (Xbrane), formerly Xbrane Bioscience AB is a biopharmaceutical company that develops and manufactures complex generic products. The company's product portfolio includes biosimilars and long acting injectables developed for people suffering from critical diseases. It combines its proprietary microsphere and protein production technology platforms to develop and produce generics drugs for controlled release of the active substance through encapsulation in microspheres. The company's products find application in treating diseases across various therapeutic areas including acromegaly and neuroendocrine tumours, prostate cancer, endometriosis and uterine fibroids; age-related macular degeneration and macular oedema, among others. Xbrane is headquartered in Stockholm, Sweden.

Xbrane Biopharma AB (XBRANE)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Xbrane Biopharma AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Xbrane Biopharma AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Xbrane Biopharma AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Xbrane Biopharma AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Xbrane Biopharma AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Xbrane Biopharma AB, Pharmaceuticals & Healthcare, Deal Details 10

Partnerships 10

Xbrane Biopharma and STADA Arzneimittel Enter into Co-Development Agreement 10

Xbrane Biopharma to Enter into Distribution Agreement for Spherotide in China 11

XBrane Biopharma Enters into Distribution Agreement with Helvetic BioPharma for Xlucane 12

Xbrane Bioscience Enters into Distribution Agreement with Pooyesh Darou Pharma 13

Licensing Agreements 14

China Resources Pharma Enters into Licensing Agreement with Xbrane Biopharma 14

China Resources Pharma to Enter into Licensing Agreement with Xbrane Biopharma 15

BioAvenir Enters into Licensing Agreement with Xbrane Biopharma 16

Equity Offering 17

Xbrane Biopharma Raises USD2.3 Million in Private Placement of Shares 17

Xbrane Biopharma Raises USD11.6 Million in Rights Offering of Shares 19

Acquisition 20

Xbrane Bioscience Acquires Primm Pharma 20

Xbrane Biopharma AB-Key Competitors 21

Xbrane Biopharma AB-Key Employees 22

Xbrane Biopharma AB-Locations And Subsidiaries 23

Head Office 23

Other Locations & Subsidiaries 23

Recent Developments 24

Financial Announcements 24

Aug 24, 2018: Xbrane Biopharma releases interim report for the second quarter of 2018 24

May 14, 2018: Xbrane Biopharma Releases Interim Report for the First Quarter of 2018 25

Feb 28, 2018: Xbrane Biopharma releases year-end report for 2017 26

Nov 13, 2017: Xbrane Biopharma releases interim report for the period July to September 2017 27

Aug 31, 2017: Xbrane Biopharma Releases Interim Report for the Period April-June 2017 28

May 18, 2017: Xbrane Biopharma releases interim report for the period January-March 2017 29

Feb 27, 2017: Xbrane Biopharma releases 2016 Year End Report 30

Corporate Communications 31

Dec 13, 2017: Xbrane Biopharma informs about changes in management team 31

May 04, 2017: Xbrane Biopharma recruits CFO and Head of Investor Relations 32

Product News 33

Sep 10, 2018: Xbrane Biopharma announces product portfolio update with a new full strategic focus on biosimilars 33

Apr 11, 2017: Xbrane Biopharma Reports Positive In-vivo Efficacy Data On Spherotide 34

Mar 27, 2017: Xbrane Biopharma Delivers First Batch Of Spherotide To A Value Of 7 Msek 35

Other Significant Developments 36

May 24, 2018: Announcement from Xbrane Biopharma's annual general meeting 36

Appendix 38

Methodology 38

About GlobalData 38

Contact Us 38

Disclaimer 38


List Of Figure

List of Figures

Xbrane Biopharma AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Xbrane Biopharma AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Xbrane Biopharma AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Xbrane Biopharma AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Xbrane Biopharma AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Xbrane Biopharma AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Xbrane Biopharma AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Xbrane Biopharma AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8


List Of Table

List of Tables

Xbrane Biopharma AB, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Xbrane Biopharma AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Xbrane Biopharma AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Xbrane Biopharma AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Xbrane Biopharma AB, Deals By Therapy Area, 2012 to YTD 2018 8

Xbrane Biopharma AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Xbrane Biopharma and STADA Arzneimittel Enter into Co-Development Agreement 10

Xbrane Biopharma to Enter into Distribution Agreement for Spherotide in China 11

XBrane Biopharma Enters into Distribution Agreement with Helvetic BioPharma for Xlucane 12

Xbrane Bioscience Enters into Distribution Agreement with Pooyesh Darou Pharma 13

China Resources Pharma Enters into Licensing Agreement with Xbrane Biopharma 14

China Resources Pharma to Enter into Licensing Agreement with Xbrane Biopharma 15

BioAvenir Enters into Licensing Agreement with Xbrane Biopharma 16

Xbrane Biopharma Raises USD2.3 Million in Private Placement of Shares 17

Xbrane Biopharma Raises USD11.6 Million in Rights Offering of Shares 19

Xbrane Bioscience Acquires Primm Pharma 20

Xbrane Biopharma AB, Key Competitors 21

Xbrane Biopharma AB, Key Employees 22

Xbrane Biopharma AB, Subsidiaries 23

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Xbrane Biopharma AB, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.